Last updated: 2026-09-23 23:18:20. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Nuvation Bio Inc. (NUVB) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NYSE. The stock is currently priced at $5.71, with a market capitalization of $2.13B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2.99 to $9.75. This page covers its latest market performance, valuation, price trends and company information.
$2.13B | |
$6.07 | |
$15.23 | |
$0.95 | |
$6.10 | |
3.89M | |
6.78M | |
-- | |
$9.75 | |
$2.99 | |
-- | |
-- |
Nuvation Bio Inc. (NUVB) is trading at $5.80 in after-hours trading as of 2026-09-23 23:00:00, down 5.00% ($0.30) from the regular-session close of $6.10.
After-hours trading shows how investors are pricing NUVB after the regular session closes. The current after-hours price is below the regular-session close, indicating cautious after-hours sentiment.
Over the past seven days, Nuvation Bio Inc. (NUVB) moved from $5.94 to $5.71, representing a decline of 3.96% ($0.24).
The stock traded between $5.63 and $6.26 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 5.34 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 40.2%
NUVB is currently trading at $5.71, placing it 40.2% of the way from its 52-week low of $2.99 to its 52-week high of $9.75. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 305 |
| Exchange | NYSE |
| Company Website |
Eligible investors can buy real shares of Nuvation Bio Inc. (NUVB) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.